替尔泊肽治疗与肥胖或超重伴糖尿病前期或血糖正常人群β细胞功能及胰岛素敏感性相关变化:SURMOUNT-1试验事后分析
本文为SURMOUNT-1试验事后分析,纳入2539例BMI≥27 kg/m²且伴糖尿病前期或血糖正常的肥胖/超重成人,比较替尔泊肽与安慰剂治疗72周对口服葡萄糖耐量试验模型参数的影响。结果显示替尔泊肽与体重下降及胰岛素敏感性和β细胞功能改善相关,β细胞功能改善主要与替尔泊肽治疗相关。
要点
- 替尔泊肽治疗72周与肥胖/超重成人胰岛素敏感性和β细胞功能改善相关。
- β细胞功能改善主要与替尔泊肽治疗相关,胰岛素敏感性改善主要与体重下降相关。
- 上述改善在糖尿病前期和血糖正常参与者中均可见,部分独立于体重下降。
核心结论
- 在无2型糖尿病的肥胖/超重成人中,替尔泊肽治疗与β细胞功能和胰岛素敏感性改善相关,部分独立于体重下降。
研究设计与样本
- SURMOUNT-1试验的事后分析,比较替尔泊肽与安慰剂,纳入2539例基线BMI≥27 kg/m²且伴糖尿病前期或血糖正常的参与者,治疗72周。
- 通过口服葡萄糖耐量试验评估模型推导的β细胞功能和胰岛素敏感性参数。
主要发现
- 第72周时,替尔泊肽治疗与体重下降以及总体和糖尿病前期或血糖正常参与者中胰岛素敏感性和β细胞功能指标的改善相关。
- 多变量回归模型中,胰岛素敏感性改善主要与体重下降相关,部分与替尔泊肽治疗相关;β细胞功能增强主要与替尔泊肽治疗相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We assessed insulin sensitivity and β-cell function in adults with obesity/overweight, without diabetes, treated with tirzepatide for 72 weeks. RESEARCH DESIGN AND METHODS: This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline. Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests. RESULTS: At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures overall and in participants with prediabetes or normoglycemia. In multivariate regression models, improvements in insulin sensitivity were associated mostly with weight reduction and partly with tirzepatide treatment, whereas enhancement in β-cell function was mostly associated with tirzepatide treatment. CONCLUSIONS: In adults with obesity/overweight without type 2 diabetes, tirzepatide treatment was associated with improved β-cell function and insulin sensitivity, partly independent of weight reduction.
引用
- Mari A, Stefanski A, van Raalte DH, et al. Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. Diabetes Care. 2025. PMID: 40694530. doi:10.2337/dc25-0763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。